Show simple item record

dc.contributor.authorPinkham, Mark B
dc.contributor.authorWhitfield, Gillian A
dc.contributor.authorBrada, M
dc.date.accessioned2015-02-25T11:59:36Z
dc.date.available2015-02-25T11:59:36Z
dc.date.issued2015-02-06
dc.identifier.citationNew Developments in Intracranial Stereotactic Radiotherapy for Metastases. 2015: Clin Oncolen
dc.identifier.issn1433-2981
dc.identifier.pmid25662094
dc.identifier.doi10.1016/j.clon.2015.01.007
dc.identifier.urihttp://hdl.handle.net/10541/345298
dc.description.abstractBrain metastases are common and the prognosis for patients with multiple brain metastases treated with whole brain radiotherapy is limited. As systemic disease control continues to improve, the expectations of radiotherapy for brain metastases are growing. Stereotactic radiosurgery (SRS) as a high precision localised irradiation given in a single fraction prolongs survival in patients with a single brain metastasis and functional independence in those with up to three brain metastases. SRS technology has become commonplace and is available in many radiation oncology and neurosurgery departments. With increasing use there is a need for appropriate patient selection, refinement of dose-fractionation and safe integration of SRS with other treatment modalities. We review the evidence for current practice and new developments in the field, with a specific focus on patient-relevant outcomes.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Clinical oncology (Royal College of Radiologists (Great Britain))en
dc.titleNew Developments in Intracranial Stereotactic Radiotherapy for Metastases.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalClinical Oncologyen
html.description.abstractBrain metastases are common and the prognosis for patients with multiple brain metastases treated with whole brain radiotherapy is limited. As systemic disease control continues to improve, the expectations of radiotherapy for brain metastases are growing. Stereotactic radiosurgery (SRS) as a high precision localised irradiation given in a single fraction prolongs survival in patients with a single brain metastasis and functional independence in those with up to three brain metastases. SRS technology has become commonplace and is available in many radiation oncology and neurosurgery departments. With increasing use there is a need for appropriate patient selection, refinement of dose-fractionation and safe integration of SRS with other treatment modalities. We review the evidence for current practice and new developments in the field, with a specific focus on patient-relevant outcomes.


Files in this item

This item appears in the following Collection(s)

Show simple item record